Lupin launches Moxifloxacin Ophthalmic Solution USP 0.5%

Lupin launches Moxifloxacin Ophthalmic Solution USP 0.5%

292
Medicine Injection
Picture: Pixabay

Mumbai: Pharmamajor Lupin Limited (Lupin) announced the launch of Moxifloxacin Ophthalmic Solution USP, 0.5%, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.

The product would be manufactured at Lupin’s Pithampur (Unit-II) facility, India.

Moxifloxacin Ophthalmic Solution USP, 0.5% is the AT2-rated generic equivalent of Moxeza® of Novartis.

Also read: USFDA inspection at Lupin with 2 observations

It is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of certain organisms.

Moxifloxacin Ophthalmic Solution USP, 0.5% (RLD: Moxeza®) had an annual sales of approximately USD 10 million in the U.S. (IQVIA MAT December 2019).

LEAVE A REPLY

Please enter your comment!
Please enter your name here